PEN vs. GMED, STVN, TFX, GKOS, SOLV, HAE, MMSI, INSP, PODD, and SWAV
Should you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include Globus Medical (GMED), Stevanato Group (STVN), Teleflex (TFX), Glaukos (GKOS), Solventum (SOLV), Haemonetics (HAE), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), Insulet (PODD), and Shockwave Medical (SWAV). These companies are all part of the "surgical & medical instruments" industry.
Globus Medical (NYSE:GMED) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability.
Globus Medical presently has a consensus price target of $66.50, indicating a potential upside of 3.26%. Penumbra has a consensus price target of $300.64, indicating a potential upside of 47.71%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than Globus Medical.
Penumbra received 248 more outperform votes than Globus Medical when rated by MarketBeat users. Likewise, 80.43% of users gave Penumbra an outperform vote while only 67.79% of users gave Globus Medical an outperform vote.
Penumbra has a net margin of 8.52% compared to Penumbra's net margin of 3.51%. Penumbra's return on equity of 8.82% beat Globus Medical's return on equity.
In the previous week, Globus Medical had 8 more articles in the media than Penumbra. MarketBeat recorded 14 mentions for Globus Medical and 6 mentions for Penumbra. Penumbra's average media sentiment score of 0.73 beat Globus Medical's score of 0.46 indicating that Globus Medical is being referred to more favorably in the media.
Globus Medical has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
Globus Medical has higher revenue and earnings than Penumbra. Penumbra is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 24.3% of Globus Medical shares are owned by company insiders. Comparatively, 5.0% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Globus Medical beats Penumbra on 10 of the 18 factors compared between the two stocks.
Get Penumbra News Delivered to You Automatically
Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Penumbra Competitors List
Related Companies and Tools
